Theracryf Income Statement

Financials in millions GBP. Fiscal year is April - March.

Millions GBP. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '25 Sep 30, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Revenue	-	-	0.4	0.44	-	0.19
Revenue Growth (YoY)	-	-	-10.41%	-	-	-
Cost of Revenue	2.23	2.11	3.95	5.53	3.18	3.39
Gross Profit	-2.23	-2.11	-3.55	-5.09	-3.18	-3.2
Selling, General & Admin	0.01	0.01	0.02	0.01	0.01	0.02
Operating Expenses	0.01	0.01	0.02	0.01	0.01	0.02
Operating Income	-2.25	-2.12	-3.57	-5.1	-3.19	-3.21
Interest & Investment Income	0.06	0.01	-	0.1	0.02	-
Other Non Operating Income (Expenses)	0.03	0.03	-	-	-	-
EBT Excluding Unusual Items	-2.15	-2.09	-3.57	-5.01	-3.17	-3.21
Pretax Income	-2.15	-2.09	-3.57	-5.01	-3.17	-3.21
Income Tax Expense	-0.14	-0.14	-0.43	-0.96	-0.44	-0.54
Net Income	-2.01	-1.94	-3.14	-4.04	-2.73	-2.67
Net Income to Common	-2.01	-1.94	-3.14	-4.04	-2.73	-2.67
Shares Outstanding (Basic)	1,399	538	275	275	275	147
Shares Outstanding (Diluted)	1,399	538	275	275	275	147
Shares Change (YoY)	300.38%	95.83%	-	-	86.97%	13.69%
EPS (Basic)	-0.00	-0.00	-0.01	-0.01	-0.01	-0.02
EPS (Diluted)	-0.00	-0.00	-0.01	-0.01	-0.01	-0.02
Free Cash Flow	-1.7	-2.37	-3	-4.13	-2.59	-2.93
Free Cash Flow Per Share	-0.00	-0.00	-0.01	-0.01	-0.01	-0.02
Operating Margin	-	-	-900.51%	-1154.75%	-	-1656.19%
Profit Margin	-	-	-792.17%	-914.71%	-	-1378.35%
Free Cash Flow Margin	-	-	-756.57%	-933.94%	-	-1510.83%
EBITDA	-2.21	-2.06	-3.55	-5.09	-3.18	-3.2
D&A For EBITDA	0.04	0.07	0.01	0.01	0.02	0.02
EBIT	-2.25	-2.12	-3.57	-5.1	-3.19	-3.21

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.